Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.
Aged
Alleles
Alzheimer Disease
/ genetics
Amyloid
Apolipoprotein E4
/ genetics
Biomarkers
/ cerebrospinal fluid
Cognitive Dysfunction
/ pathology
Disease Progression
Female
Genotype
Humans
Longitudinal Studies
Male
Positron-Emission Tomography
Prodromal Symptoms
Sex Factors
Time Factors
tau Proteins
/ cerebrospinal fluid
APOE
Alzheimer's disease
Clinical setting
Dementia
Disease duration
Multistate model
Preclinical
Prodromal
Progression
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
13
12
2018
revised:
28
02
2019
accepted:
01
04
2019
pubmed:
6
6
2019
medline:
11
7
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.
Identifiants
pubmed: 31164314
pii: S1552-5260(19)30084-6
doi: 10.1016/j.jalz.2019.04.001
pmc: PMC6646097
mid: NIHMS1531214
pii:
doi:
Substances chimiques
Amyloid
0
Apolipoprotein E4
0
Biomarkers
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
888-898Subventions
Organisme : NIA NIH HHS
ID : P01 AG043362
Pays : United States
Investigateurs
B Vellas
(B)
E Reynish
(E)
P J Ousset
(PJ)
S Andrieu
(S)
A Burns
(A)
F Pasquier
(F)
G Frisoni
(G)
E Salmon
(E)
J P Michel
(JP)
D S Zekry
(DS)
M Boada
(M)
J F Dartigues
(JF)
M G M Olde-Rikkert
(MGM)
A S Rigaud
(AS)
B Winblad
(B)
A Malick
(A)
A Sinclair
(A)
L Frölich
(L)
P Scheltens
(P)
C Ribera
(C)
J Touchon
(J)
P Robert
(P)
A Salva
(A)
G Waldemar
(G)
R Bullock
(R)
M Tsolaki
(M)
G Rodriguez
(G)
L Spiru
(L)
R W Jones
(RW)
G Stiens
(G)
G Stoppe
(G)
M Eriksdotter Jönhagen
(M)
A Cherubini
(A)
P M Lage
(PM)
T Gomez-Isla
(T)
V Camus
(V)
E Agüera-Morales
(E)
F Lopez
(F)
S Andrieu
(S)
S Savy
(S)
C Cantet
(C)
N Coley
(N)
Informations de copyright
Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Références
Arch Neurol. 2009 Sep;66(9):1151-7
pubmed: 19752306
Alzheimers Dement. 2014 Oct;10(5 Suppl):S430-52
pubmed: 25341459
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Alzheimers Res Ther. 2016 Jun 06;8(1):22
pubmed: 27263933
Brain. 2015 May;138(Pt 5):1327-38
pubmed: 25693589
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Alzheimers Dement. 2018 Apr;14(4):462-472
pubmed: 29396108
Lancet Neurol. 2016 Jan;15(1):56-64
pubmed: 26597325
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
JAMA. 2015 May 19;313(19):1924-38
pubmed: 25988462
Arch Neurol. 2008 Aug;65(8):1091-5
pubmed: 18695059
Lancet Neurol. 2009 Jul;8(7):619-27
pubmed: 19523877
Int Psychogeriatr. 2012 Jul;24(7):1034-45
pubmed: 22325331
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
JAMA Neurol. 2018 Aug 1;75(8):970-979
pubmed: 29710225
Arch Gen Psychiatry. 2012 Jan;69(1):98-106
pubmed: 22213792
Ann Neurol. 2017 Nov;82(5):706-718
pubmed: 29023983
Dement Geriatr Cogn Disord. 2014;38(5-6):286-99
pubmed: 24992891
Alzheimers Dement. 2018 Aug;14(8):981-988
pubmed: 29802030
Lancet Neurol. 2018 May;17(5):434-444
pubmed: 29555425
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44
pubmed: 16473978
Alzheimers Dement. 2018 Jun;14(6):734-742
pubmed: 29352855
Semin Oncol. 2010 Jun;37(3):202-15
pubmed: 20709205
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
PLoS Med. 2017 Mar 21;14(3):e1002254
pubmed: 28323826
Lancet Neurol. 2013 Apr;12(4):357-67
pubmed: 23477989
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Alzheimers Dement. 2010 May;6(3):202-11.e7
pubmed: 20451868
JAMA Neurol. 2017 Oct 1;74(10):1178-1189
pubmed: 28846757
J Am Med Dir Assoc. 2015 Dec;16(12):1104.e1-7
pubmed: 26593306
Lancet Neurol. 2013 Oct;12(10):957-65
pubmed: 24012374
J Neurol Neurosurg Psychiatry. 2007 May;78(5):461-4
pubmed: 17098843
Neurology. 2014 May 20;82(20):1760-7
pubmed: 24748674
Neurology. 2012 Oct 23;79(17):1809-16
pubmed: 23019259
J Alzheimers Dis. 2014;41(1):313-27
pubmed: 24614907
Alzheimers Dement. 2018 Feb;14(2):121-129
pubmed: 29233480
Lancet. 2016 Jul 30;388(10043):505-17
pubmed: 26921134
Lancet Neurol. 2016 Apr;15(5):455-532
pubmed: 26987701
Neuroepidemiology. 2007;29(1-2):29-38
pubmed: 17898521
JAMA Neurol. 2018 Apr 1;75(4):488-494
pubmed: 29356823
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
Alzheimers Res Ther. 2018 Feb 20;10(1):23
pubmed: 29458426